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ABSTRACT
This study aimed to evaluate human antibody responses to diphtheria toxin subunits in various age
groups. Antibodies against the intact diphtheria toxin and the diphtheria toxin subunits A and B were
evaluated in 1319 individuals using a double-antigen ELISA. Although high levels of protection (83.6%,
95% CI 79.2–87.4) were found in children and adolescents, the middle-aged adult population was less
protected (28.8%, 95% CI 24.3–33.6). An increase in age was associated with a decrease in the frequency
of protected individuals in the 0–39-year age group (p <0.001). Anti-subunit B levels correlated well
(p <0.01) with levels of antibodies against the intact toxin. In children aged £16 years, the intervals at
which the peaks in geometric mean titres of anti-subunit B antibodies were observed were found to
correlate with the ages at which booster doses are administered. Overall, males appeared to be more
protected than females (OR 1.67, 95% CI 1.34–2.08, p <0.001). A small group of individuals had
antibody levels of ‡0.1 IU ⁄mL against the intact toxin, but did not have protective antibody against
subunit B. Determination of anti-subunit B antibody levels should help in evaluating the effectiveness of
diphtheria boosters and other aspects of diphtheria immunity.
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INTRODUCTION
A combination of low coverage rates among
children and an immunity gap in adults creates
the potential for a diphtheria epidemic that could
easily occur following the importation of cases
from countries in which diphtheria is still
endemic [1–3]. In the early 1990s, an outbreak
of diphtheria occurred in the Russian Federation
and Newly Independent States, with limited
numbers of cases in other north-eastern European
countries [1,3]. There have subsequently been
numerous studies aimed at understanding the
factors behind the epidemic and at identifying
possible lessons for the next such unpredictable
occurrence [1]. In this respect, the proportion of
protected individuals in the general population
still seems to be far from satisfactory in develop-
ing countries [4,5].
In Turkey, the Expanded Immunisation
Programme was started in 1985, with primary
diphtheria immunisation scheduled at the ages
of 2, 3 and 4 months, and a booster at
16–24 months, using diphtheria, tetanus and
pertussis. Additionally, at the ages of 6–7 years
and 13–14 years, which correspond to the ﬁrst
and eighth class of primary education, respec-
tively, booster doses are given as low-dose
diphtheria toxoid in combination with tetanus
toxoid, with this schedule being implemented
since 2003 for diphtheria. Thereafter, boosters are
recommended every 10 years, but are not rou-
tinely administered. Mortality in Turkey caused
by diphtheria decreased from 1.78 ⁄million inhab-
itants in 1970 to 0.26 ⁄million inhabitants in 1984.
After the implementation of the immunisation
programme, the total number of cases reported
between 1985 and 2004 was 427, with 124
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cases occurring during 1993–1996 (http://www.
saglik.gov.tr/extras/istatistikler/temel2004/tablo-
41.htm). It therefore seems important to address
the proﬁle of individual countries with respect to
diphtheria immunity.
The question of whether immunity against
intact diphtheria toxoid parallels that of immu-
nity against diphtheria toxoid subunits also seems
to be important. Certain aspects of immunity
against diphtheria still have to be elucidated,
since there are reports of cases of diphtheria
despite recent booster doses and very high levels
of protective antibody [6]. Diphtheria toxin has
two subunits. In general, subunit B is the major
domain involved in attachment to cellular
surfaces, and subunit A is responsible for the
cytosolic inhibition of elongation factor-2, and
hence cellular damage [7]. It is well-known that
antibodies raised against different epitopes on the
diphtheria toxin have different effector functions
[8]. In addition, isotypic differences exist in
antibodies raised against certain antigenic deter-
minants of the diphtheria toxin [9]. The present
study aimed to evaluate the distribution of
human antibody responses against diphtheria by
measuring anti-diphtheria subunit antibodies.
Possible correlations between immunity against
intact diphtheria toxin and diphtheria subunits
A and B were investigated using an in-house
double-antigen ELISA method.
MATERIALS AND METHODS
Study population
The study was performed using residual sera collected during
routine laboratory testing at the Gazi University Faculty of
Medicine, afﬁliated to Gazi Hospital, Ankara, Turkey, between
September 2004 and January 2005. Randomly collected residual
serawerestratiﬁedforageandgenderaccordingto thehospital’s
database; speciﬁc data regarding vaccination history were not
available. In total, 1319 sera stored at )85C were available for
the study.All sampleswere tested, using the same experimental
conditions, during a 24-h period. Anti-diphtheria toxin, and
anti-subunit A and anti-subunit B antibodymeasurementswere
performed simultaneously for each sample.
Diphtheria toxin and diphtheria anti-toxin standard
Diphtheria toxin (440 Lf ⁄mL) was obtained from the Reﬁk
Saydam Hıfzısıhha Institute, Vaccine Development Centre,
Ankara. This toxin is used for diptheria vaccine prepara-
tion in Turkey. The diphtheria anti-toxin used was Diph-
theria Antitoxin Human Standard (Code No. 00 ⁄ 496;
National Institute for Biological Standards and Control,
London, UK).
Fragmentation of diphtheria toxin and subunit yield
Diphtheria toxin was fragmented into subunits A and B as
described previously [10]. In brief, the toxin was treated with
freshly dissolved trypsin for 15 min at 37C in 50 mM Tris-
HCl, 1 mM EDTA, pH 8.2. Trypsinised diphtheria toxin was
subjected to SDS-PAGE in 10% w ⁄v gels under reducing
conditions as described by Laemmli [11]. Following electro-
phoresis, relevant bands were excised separately and eluted
in distilled water at 4C for 24 h. The eluate was dialysed
(molecular size cut-off of 6000–8000 Da; Spectrum Medical
Industries Inc., Los Angeles, CA, USA) against 10 mM
phosphate-buffered saline, pH 7.4. The protein content of
the dialysed eluates of the diphtheria toxin subunits A and B
was determined by HPLC (1100 Series HPLC System;
Agilent Technologies, Waldbronn, Germany) with bovine
serum albumin as the standard. The purity of the intact
diphtheria toxin, subunit A and subunit B eluates was
checked using SDS-PAGE. Subunits were kept at )85C until
use.
In-house double-antigen ELISA
The in-house double-antigen ELISA was performed as
described previously [10,12]. The results obtained with the
double-antigen ELISA correlate well with those obtained
using the toxin neutralisation assay [13]. In brief, high-
binding-capacity microtitre plates (Costar; Corning Inc.,
Corning, NY, USA) were coated with diphtheria toxin
(1 mg ⁄L in 0.05 M carbonate–bicarbonate buffer, pH 9.6)
and then incubated at 4C overnight. After automated
washing (Columbus Plus ELISA Washer; Tecan, Gro¨dig,
Austria) three times with phosphate-buffered saline contain-
ing Tween-20 0.05% v ⁄v (PBS-T), the plates were blocked
with phosphate-buffered saline containing bovine serum
albumin 1% w ⁄v (200 lL ⁄well) for 3 h at room temperature.
Serum samples were diluted 1:100 in PBS-T containing bovine
serum albumin 1% w ⁄v before adding 100 lL to each well of
the microtitre plates. Serially diluted reference serum was
included on each microtitre plate to obtain a calibration
curve. Diluted serum samples and standards were incubated
for 1 h at 37C. After washing three times with PBS-T, 100 lL
of diphtheria toxin labelled with horseradish peroxidase was
added to each well and incubated for a further 1 h at 37C.
The plates were then again washed three times with PBS-T,
and this was followed by the addition of 100 lL of 3,3¢,5,5¢-
tetramethylbenzidine substrate to each well and incubation
for 15 min at room temperature. The reaction was stopped by
adding 100 lL of 0.5 M H2SO4 to each well. Optical densities
were read using a Sunrise ELISA Reader (Tecan, Gro¨dig,
Austria). The anti-diphtheria ELISA run under these exper-
imental conditions had a minimum detection limit of
0.007 IU ⁄mL with the Diphtheria Antitoxin Human Serum
standard. The same procedures and reagents were used for
the in-house anti-subunit A and anti-subunit B ELISAs,
except that the coating antigen was subunit A or subunit B,
respectively.
Data evaluation and statistical analyses
The standard diphtheria anti-toxin human serum used was
expressed in terms of IU ⁄mL. Antibody titres to diphtheria
subunits A and B were accordingly expressed as IU
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equivalents ⁄mL, as described previously [9]. The internation-
ally accepted classiﬁcation of anti-diphtheria antibody
concentrations was used to classify quantitative results [14].
Differences in proportions of protected individuals in various
age groups were evaluated by chi-square tests, with p <0.05
regarded as statistically signiﬁcant. Binary logistic regression
analyses were carried out to examine associations between the
frequencies of individuals with protective antibody levels and
variables such as age and gender. For the models, antibody
levels, expressed as either IU ⁄mL or IU equivalents ⁄mL,
were coded as dichotomous dependent variables by classifying
‡0.1 as protected or <0.1 as insufﬁcient or non-protected.
Model ﬁts were evaluated by )2 log likelihood tests. Statistical
analyses were performed using SPSS for Windows v.12.0 (SPSS
Inc., Chicago, IL, USA) and EpiInfo v.6.0 (CDC, Atlantic, GA,
USA).
RESULTS
Study population
In total, 1319 sera (647 from males) were included
in the study. The age of the study population
ranged from 1 to 87 years, with mean ages of 35.8
(± 21.1) and 37.6 (± 20.3) years for males and
females, respectively. The gender composition of
each age group was as follows: 0–9 years, 87
males (M), 64 females (F), total 151; 10–19 years,
101 M, 89 F, total 190; 20–29 years, 79 M, 102 F,
total 181; 30–39 years, 82 M, 105 F, total 187;
40–49 years, 98 M, 97 F, total 195; 50–59 years,
107 M, 104 F, total 211; and 60+ years, 93 M,
111 F, total 204.
Fragmentation of diphtheria toxin
Intact diphtheria toxin treated with a predeﬁned
concentration of trypsin was shown to be
cleaved effectively into subunits A and B. The
samples gave a gel pattern consistent with the
known molecular sizes of intact diphtheria toxin,
diphtheria subunit A and diphtheria subunit B
[10].
Immunity against intact diphtheria toxin
The percentage of individuals protected against
diphtheria (‡0.1 IU ⁄mL) in various age groups is
summarised in Fig. 1. Overall, 53.8%
(95% CI 51.1–56.6) of the study population had
antibody levels of ‡0.1 IU ⁄mL against intact
diphtheria toxin. Proportions of protected males
(60.4%, 95% CI 56.6–64.2) were signiﬁcantly
higher than those of females (47.5%,
95% CI 43.6–51.3) (p <0.001). The highest protec-
tion was observed in the groups aged 0–9 years
(87.4%, 95% CI 81.1–92.3) and 10–19 years
(80.5%, 95% CI 74.2–88.9), and the lowest protec-
tion was observed in the groups aged 30–39 years
(25.7%, 95% CI 19.6–32.6) and 40–49 years
(31.8%, 95% CI 25.3–38.8). The ﬁgure of 83.6%
(95% CI 79.2–87.4) protection for the group aged
0–19 years decreased to 28.8% (95% CI 24.3–33.6)
for the group aged 30–49 years (p <0.001). The
proportion of individuals protected against
diphtheria increased gradually for individuals
aged +40 years. Thus, about one-third (31.8%,
95% CI 25.3–38.8) of individuals aged 40–49 years
were regarded as protected, compared with 47.4%
(95% CI 40.5–54.4) and 60.3% (95% CI 53.2–66.8)
for the groups aged 50–59 years and 60+ years,
respectively. The increases in the proportion of
protected individuals between the groups aged
40–49 and 50–59 years, and between the groups
aged 50–59 and 60+ years, were statistically signif-
icant (p <0.05). Individuals with antibody levels
of <0.01 IU ⁄mL against intact diphtheria toxin
comprised 12.3%, 54.6%, 51.3% and 29.4% of the
groups aged 0–19, 20–39, 40–59, and 60+ years,
respectively.
The overall geometric mean antibody titre
(GMT) of intact diphtheria toxin antibody for
the entire population of 1319 individuals was
0.11 IU ⁄mL. GMTs for the groups aged 0–9,
Fig. 1. Distribution of diphtheria
immunity according to age group
and gender, as measured by anti-
bodies against diphtheria toxin.
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10–19, 20–29, 30–39, 40–49, 50–59 and 60+ years
were 3.78, 1.49, 0.071, 0.0073, 0.013, 0.052 and
0.153 IU ⁄mL, respectively. Males had higher
GMTs than females in all age groups. In the
group aged £16 years, GMTs peaked at 4
(11.7 IU ⁄mL), 8 (9.18 IU ⁄mL), and 14 (8.09
IU ⁄mL) years.
Immunity against diphtheria subunits A and B
Overall, 35.7% (95% CI 33.1–38.4) of the study
population had a protective antibody level
against subunit A, and 50.6% (95% CI 47.8–53.3)
against subunit B. Males showed higher antibody
levels against both diphtheria toxin subunits than
females (p <0.05).The distribution of immunity
against diphtheria subunits A and B according to
age group is summarised in Fig. 2. The lowest
protection was observed for the group aged
30–39 years against both subunit A (15%,
95% CI 10.2–20.9) and subunit B (27.3%,
95% CI 21.0–34.3). Thus, the immunological gap
observed for the intact diphtheria toxin in the
group aged 30–49 years was also observed for
diphtheria subunits A and B. Correlation coefﬁ-
cients for antibody concentrations against intact
diphtheria toxin were calculated as 0.796
(Pearson, p <0.01) and 0.858 (Pearson, p <0.01)
for anti-subunit A and anti-subunit B concentra-
tions, respectively.
The group aged £16 years was analysed further
with respect to the ages at which booster doses
were administered. Within this group, GMTs of
anti-subunit B antibodieswere 8.65, 6.8 and 3.83 IU
equivalents ⁄mL at 4, 8 and 14 years, respectively,
whereas GMTs of anti-subunit A antibodies were
0.83, 4.84 and 0.89 IU equivalents ⁄mL, respec-
tively. Among individuals aged £16 years with
antibody titres of ‡0.1 IU ⁄mL against intact diph-
theria toxin (n = 234), 58 (24.8%, 95% CI 19.4–
30.8) had higher antibody titres against subunit A,
whereas 168 (71.8%, 95% CI 65.6–77.5) had higher
titres against subunit B. Eight (3.4%, 95% CI 1.5–
6.6) individuals had equal antibody titres against
both subunits of the diphtheria toxin. When
individuals with antibody titres of ‡0.1 IU ⁄mL
against intact diphtheria toxin (n = 710) were
analysed in detail, it was found that 37 (5.2%,
95% CI 3.7–7.1) had anti-subunit A antibodies of
‡0.1 IU equivalents ⁄mL and anti-subunit B anti-
bodies of <0.1 IU equivalents ⁄mL.
Logistic regression analyses
Since a normal distribution of protected indivi-
duals was not observed for the entire study
population, different models were examined for
deviance in order to accurately deﬁne tendencies
with respect to the observed immunological gap.
When the entire study population (n = 1319) was
taken into account, it was found that males were
protected c. 1.7-fold more than females (OR 1.67,
95% CI 1.34–2.08, p <0.001), and an increase in
age was found to be associated inversely
(OR 0.98, 95% CI 0.976–987, p <0.001) with pro-
tective levels of antibody against the intact diph-
theria toxin.
The study population was further analysed by
division into two subgroups. In the group aged
0–39 years (n = 709), males were signiﬁcantly
(p 0.001) more protected than females (OR 1.82,
95% CI 1.28–2.59), and an increase in age was
signiﬁcantly (p <0.001) associated with a decrease
in the proportion of protected individuals
(OR 0.89, 95% CI 0.88–0.91). In the group aged
‡40 years (n = 610), males were more protected
than females (OR 1.60, 95% CI 1.15–2.24, p 0.006),
and an increase in age correlated with an increase
Fig. 2. Distribution of immunity
against diphtheria subunits A and
B according to age group, as mea-
sured by antibodies (‡0.1 IU equiv-
alents ⁄mL).
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in the proportion of protected individuals
(OR 1.06 95% CI 1.04–1.08, p <0.001).
Similar analyses were performed for diphtheria
subunits A and B. For the group aged 0–39 years,
an increase in age was associated with a decrease
in the proportion of protected individuals
(OR 0.91, 95% CI 0.89–0.93, p <0.001, and
OR 0.90, 95% CI 0.89–0.92, p <0.001, respec-
tively). In the ﬁrst four decades of life, males
were more likely to be protected against subunit
A (OR 1.41, 95% CI 1.01–1.97, p <0.05) and sub-
unit B (OR 1.52, 95% CI 1.08–2.14, p <0.05).
Among individuals aged ‡40 years, males were
also more likely to be protected against subunit B
(OR 1.52, 95% CI 1.09–2.11, p 0.012).
DISCUSSION
Diphtheria is well-controlled in countries that
have implemented diphtheria toxoid vaccination.
The diphtheria epidemics that started in the
Newly Independent States during the early
1990s drew attention to a disease of the pre-
vaccine era that was thought to have been
eliminated at the beginning of the 1980s [3].
Turkey was also affected during the epidemic in
the Newly Independent States, with 124 cases
being reported between 1993 and 1996 (http://
www.saglik.gov.tr/extras/istatistikler/temel2004/
tablo-41.htm). Although associated with higher
morbidity rates, the total number of cases
reported from some of the Baltic states, e.g., Estonia
and Lithuania, were fewer than those reported
from Turkey during the same period [1,15].
According to the European Laboratory Working
Group on Diphtheria, the number of cases and
carriers of diphtheria is still regarded as being high
in Turkey, despite the expanded immunisation
programme implemented in 1985 [16].
The reasonably high level of protection revealed
by the present study among children and adoles-
cents aged <20 years can be attributed to the
expanded immunisation programme imple-
mented in Turkey two decades ago. However,
the study also revealed a signiﬁcant immunity gap
in the adult population, which can be attributed to
the fact that adults (aged >20 years) did not
receive the primary series of diphtheria immuni-
sations during childhood. Overall, it is reasonable
to assume that the present study population
reﬂects patterns common to the pre-vaccine and
vaccine eras. The 83.6% frequency of protected
individuals aged 0–19 years decreased to 28.8%
among individuals aged 30–49 years. Moreover,
males were protected more frequently than
females, as also reported previously in The Neth-
erlands, France, Sweden and Finland [14]. Similar
data concerning the frequencies of protected
individuals and immunity gaps have been re-
ported for other European countries [17,18]. Tur-
key has an immunisation schedule similar to those
used in France and the UK. However, the propor-
tions of protected individuals were lower than
those reported in France, which may be explained
by the high vaccine coverage rate in France (98%)
and the relatively low coverage rates in Turkey
(68% in 2003 and 85% in 2004) [14,19] (http://
www.saglik.gov.tr/extras/istatistikler/temel2004/
tablo34.htm). The increased frequency of immune
individuals among elderly adults is probably
associated with the fact that natural boosting
occurs throughout life [3]. As found in countries
that implemented mass vaccination many decades
ago, the proportion of susceptible older adults in
Turkey is likely to increase in future as a result of
the expanded immunisation programme that
decreases the natural boost reservoir of Corynebac-
terium diphtheriae unless adult booster doses are
given [1,2,15].
Overall, immunity against diphtheria subunits
A and B correlated well with immunity against
the intact diphtheria toxin (Figs 1 and 2). Corre-
lation coefﬁcients for antibody concentrations
against intact diphtheria toxin and anti-subunit
antibody concentrations were calculated as 0.796
(p <0.01) and 0.858 (p <0.01) for anti-subunit A
and anti-subunit B antibodies, respectively. The
observed peaks in GMT levels for anti-subunit B
antibodies in individuals aged 4, 8 and 14 years
are in accordance with peaks in GMTs of
antibodies against the intact diphtheria toxin, but
no distinguishable peak in GMTs of anti-subunit
A antibodies was observed. It can therefore be
concluded that anti-subunit B antibody levels,
but not anti-subunit A levels, reﬂect the recom-
mended diphtheria vaccine boosters adminis-
tered according to the Turkish immunisation
policy.
Studies assessing antibodies against diphtheria
subunits in individuals are very unusual.
Although involving limited numbers of individ-
uals, two reports have demonstrated the impor-
tance of anti-subunit B antibodies in recently
vaccinated individuals [9,20]. The present study
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conﬁrmed these observations for anti-subunit B
antibodies, and expanded the conclusions to a
large population matched for age and gender.
In children and adolescents (aged £16 years)
regarded as protected (anti-diphtheria toxin
antibodies ‡0.1 IU ⁄mL), individuals with higher
titres of antibodies against subunit B predomi-
nated (71.8%) over individuals with higher titres
against subunit A (24.8%). Individuals with
antibody titres of ‡0.1 IU ⁄mL against the intact
diphtheria toxin cannot necessarily be considered
to be protected. This conclusion is based on the
ﬁnding that antibody titres of ‡0.1 IU ⁄mL
against the intact diphtheria toxin do not neces-
sarily indicate protective antibody levels against
subunit B. Thus, a subgroup of individuals
(n = 37) had protective levels of anti-diphtheria
toxin antibodies (‡0.1 IU ⁄mL) because of rela-
tively high anti-subunit A antibodies, but had
<0.1 IU equivalents ⁄mL of anti-subunit B anti-
bodies. Since diphtheria toxin subunits A and B
have different functions, antibodies raised
against these speciﬁc subunits have different
effects [8]. This ﬁnding may explain several case
reports that have described clinical diphtheria
and its complications despite high antibody
levels [6].
The risk of a diphtheria epidemic exists when
there is a combination of low vaccination
coverage in childhood and an immunity gap
in the adult population [1,21]. In such circum-
stances, in conjunction with other factors, toxi-
genic strains can spread easily among children,
and unprotected adults can acquire the disease
unless appropriate countermeasures are imple-
mented quickly [22]. It is clearly important that
future vaccines elicit high levels of anti-subunit
B antibodies, since antibodies to subunit B are
more important in providing protection against
diphtheria than those against the A subunit
[9]. Studies investigating immunity against
diphtheria should therefore also analyse immu-
nity against subunits A and B.
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